logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. A cost analysis on the pattern of asthma prescribing in the UK.

    Article - En anglais

    There is a need to establish the proportion of adult asthmatics at each step of the recommended asthma management guidelines, the cost of their prescribed treatment, and a revised cost of treatment assuming patients who were suboptimally controlled were moved up a step.

    Actual prescription and cost figures and a theoretical projection of an ideal scenario was calculated from a sample of general practices in Great Britain from the Doctors Independent Network.

    They comprised 102 nationally distributed practices and 17,206 adult patients with a diagnosis of, and prescription related to, asthma recorded between October 1993 and March 1994.

    Ninety-one per cent of patients received treatment within a recognized step of the guidelines.

    Of these, 80% were at steps 1 and 2. Employing excess inhaled beta-agonist use as a proxy for control of asthma, between 55% and 69% of patients at Steps 1-3 should receive treatment at a higher step.

    This could lead to an increased expenditure of up to £4.66 per adult patient per month.

    This would imply a rise in the annual UK cost of antiasthma prescriptions for adults from £388m to a possible £533m.

    The United Kingdom Government audit commission has suggested that current expenditure on asthma treatment appears to be insufficient.

    Using an entirely different approach this study has confirmed that a significant increase in asthma prescribing costs is likely to be needed if optimal control of asthma is to be achieved.

    Mots-clés Pascal : Asthme, Traitement, Prescription médicale, Analyse coût, Estimation coût, Royaume Uni, Europe, Recommandation, Economie santé, Evolution, Homme, Appareil respiratoire pathologie, Bronchopneumopathie obstructive

    Mots-clés Pascal anglais : Asthma, Treatment, Medical prescription, Cost analysis, Cost estimation, United Kingdom, Europe, Recommendation, Health economy, Evolution, Human, Respiratory disease, Obstructive pulmonary disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0491008

    Code Inist : 002B11B. Création : 22/03/2000.